Background Clinical trials of immunotherapy have excluded patients with pre-existing
autoimmune disease. While the safety and efficacy of single agent ipilimumab and anti-PD1 …

Background Rare cases of immune checkpoint inhibitor (ICI)-associated celiac disease (ICI-
CeD) have been reported, suggesting that disruption of tolerance mechanisms by ICIs can …

Immune checkpoint inhibitors are a novel class of cancer treatment that have improved
outcomes for a subset of cancer patients. They work by antagonising inhibitory immune …

Simple Summary Recently, cancer prognoses have improved by using a new class of drugs
called immune checkpoint inhibitors. These treatments work by helping a person's immune …

Background There is a lack of predictive markers informing on the risk of colitis in patients
treated with immune checkpoint inhibitors (ICIs). The aim of this study was to identify …

Inflammatory bowel disease (IBD) is characterized by dysregulated intestinal immune
responses. Using mass cytometry (CyTOF) to analyze the immune cell composition in the …

The gastrointestinal (GI) mucosa is among the most complex systems in the body. It has a
diverse commensal microbiome challenged continuously by food and microbial components …

Hepatocellular carcinoma (HCC) is a leading cause of cancer death globally and is rising in
incidence. Until recently, treatment options for patients with advanced stages of HCC have …

Simple Summary Hepatic and intrahepatic bile duct cancer is the sixth most frequently
diagnosed cancer in the world. A total of 830,200 people died from liver cancer globally in …

Over the past decade, the use of immune checkpoint inhibitors (ICI) has expanded across a
wide spectrum of oncology indications. Immune-related adverse events (irAE) from ICIs …